SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

GT Biopharma Inc. (GTBP)

GTBP RSS Feed
Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski, BDavid5
Search This Board: 
Last Post: 11/17/2017 12:32:21 PM - Followers: 168 - Board type: Free - Posts Today: 0


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
SureTrader
Interactive Brokers Advertisement
GTBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Current Report Filing (8-k) 11/16/2017 08:01:47 AM
GTBP News: Quarterly Report (10-q) 11/14/2017 04:17:03 PM
GTBP News: Statement of Ownership (sc 13g) 11/14/2017 10:16:50 AM
GTBP News: Current Report Filing (8-k) 10/12/2017 03:01:33 PM
GTBP News: Amended Statement of Ownership (sc 13g/a) 10/10/2017 08:25:05 AM
PostSubject
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#11350   MCET had much better, insulting lying pumpers. 10 cents. simon wagstaff 11/17/17 12:32:21 PM
#11349   Boom! You just jumped out of the capttom1 11/17/17 11:34:55 AM
#11348   I believe that also and have held on Hoopasauraus 11/17/17 10:15:49 AM
#11347   Minimum of 18 months before they submit, will simon wagstaff 11/17/17 08:06:38 AM
#11346   It will be a while but I think UaRaph 11/16/17 09:28:59 PM
#11345   Pain "Brake" refers to stopping pain. The tablets Hoopasauraus 11/16/17 03:43:59 PM
#11344   Revenue from Pain-brake? Not any time soon. They simon wagstaff 11/16/17 10:13:37 AM
#11343   They should start receiving some money from selling Gumby525 11/16/17 09:39:24 AM
#11342   Should be 10 cents or so. simon wagstaff 11/15/17 10:32:34 AM
#11341   I'm guessing this just keeps bleeding steadily lower. Mike1019 11/14/17 07:43:15 PM
#11340   Where do you see this stock going? UaRaph 11/14/17 05:33:11 PM
#11339   They just filed their 3rd Qtr Financials on scoot27 11/14/17 05:17:05 PM
#11338   GTBP has nothing to do with Car-T. simon wagstaff 11/08/17 07:25:37 AM
#11337   TIME magazine just did a article about cart Bishop123 11/08/17 06:14:19 AM
#11336   For sure, that's why I have been holding UaRaph 11/06/17 04:54:26 PM
#11335   If you're down 90% the last thing you capttom1 11/06/17 07:24:32 AM
#11334   I bought the stock OXIS before this company UaRaph 11/05/17 08:25:17 PM
#11333   WTF? Market value of $261 million? simon wagstaff 11/05/17 09:01:32 AM
#11332   The most overvalued stock in the entire OTC land munimi 10/31/17 04:23:20 PM
#11331   I didn't write it, just copied from the simon wagstaff 10/31/17 08:51:05 AM
#11330   I'm not a fan Simon but that's one presidentsclub 10/31/17 12:12:51 AM
#11329   I know so they now only have 500,000 MrBond007 10/30/17 06:56:00 PM
#11328   The reverse split already occurred a while ago. JayP-Diddy 10/30/17 11:03:02 AM
#11327   "After the completed reverse split, there will be MrBond007 10/27/17 01:57:54 PM
#11326   ONLY 496,441 Outstanding shares is this true? MrBond007 10/27/17 07:43:12 AM
#11325   Krap! Didn't stay above 7 long enough for simon wagstaff 10/26/17 03:57:38 PM
#11324   I've shorted the daylights out of this POS. simon wagstaff 10/25/17 06:41:13 AM
#11322   hell yeah baby! MrBond007 10/24/17 02:03:02 PM
#11320   GTBP Announces Approved FDA IND Transfer of Its TheOtcStockGuy 10/24/17 09:06:04 AM
#11318   Lol! Just like WE ALL know GTBP to simon wagstaff 10/22/17 04:20:06 AM
#11317   We all know you never :) MrBond007 10/22/17 02:53:21 AM
#11315   LOL! Thanks for sharing.... JayP-Diddy 10/18/17 08:57:13 AM
#11312   Thanks, I plan on it. I made so simon wagstaff 10/17/17 04:50:08 PM
#11311   GT Biopharma Announces Stock Sales Agreement with Holders JayP-Diddy 10/17/17 04:49:45 PM
#11310   please do..... JayP-Diddy 10/17/17 02:03:58 PM
#11309   More news!! http://biotechstocks.com/gt-biopharma-inc-gtbp-begins-manufacturing- Oharper 10/17/17 11:42:23 AM
#11308   I think 500,000 OS could be a mistake. MrBond007 10/17/17 09:21:28 AM
#11307   Shoot, if it hits 7 just might short simon wagstaff 10/13/17 09:47:30 PM
#11306   Thanks for posting this info. Very informative. surfgreen 10/13/17 04:09:10 PM
#11305   GTBP = Opportunity due to misinformation ... JoeDaddy 10/13/17 09:45:24 AM
#11304   Ok Shorty McShorter, that's a good one.......... I mrcraigo 10/12/17 04:12:18 PM
#11303   No support until pocket change... sicric 10/12/17 03:32:22 PM
#11302   Here is some new news http://biotechstocks.com/gt-biopharma-inc-gtbp-announces-s Oharper 10/12/17 03:27:37 PM
#11301   If they are going to uplist they will simon wagstaff 10/12/17 11:05:50 AM
#11300   From there website i signed up for news on Bishop123 10/12/17 09:46:13 AM
#11299   If you’re hoping they read out study results, Rando3 10/11/17 08:32:35 AM
#11298   What email? Can you elaborate... CashBowski 10/10/17 06:35:05 PM
#11297   I still think the ownership of OXS-1550 is simon wagstaff 10/10/17 09:38:45 AM
#11296   GTBP Announces Completion of First Four Patients in BDavid5 10/10/17 09:24:57 AM
#11295   New email out any ideas? Bishop123 10/10/17 08:39:24 AM
PostSubject